Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

McMaster University

$135,000.00

Beneficial microbes to prevent neonatal GBS disease

FY 2022-23

Summary
Streptococcus agalactiae (Group B Streptococcus; GBS), is the leading cause of invasive neonatal infections, including sepsis and meningitis. Colonized women transmit GBS to their infant during delivery in approximately 45% of births and 3% of GBS-positive infants develop GBS disease. As GBS screening during pregnancy only predicts disease in 2 of every 1000 infants, current clinical guidelines result in high rates of unnecessary antibiotic exposure, which can contribute to changes in the microbes colonizing the infant as well as increased rates of antibiotic resistance. Additionally, preventative antibiotics during delivery do not prevent late-onset (>7days after birth) GBS disease. Thus, new treatment methods are critically needed. We do not know why some GBS colonized mothers have infants with GBS disease while others do not. It is possible that beneficial vaginal microbes can protect against GBS disease. Studying the genomes of maternal vaginal microbes will allow us to discover which genes are present and what functions they have. This research will advance our understanding of the factors that influence GBS colonization and infection and ultimately inform the development of novel microbe-based treatments to prevent GBS disease. To understand the factors that influence GBS disease, healthy women undergoing vaginal, elective C-section (CS), or laboured CS will be recruited (n=50 per group) and vaginal swabs and cervical-vaginal fluid will be collected prior to delivery. Infant oral swabs, skin swabs, and stool will be collected immediately after delivery and at 1 week postpartum. Microbial DNA in these samples will be sequenced and the microbes that are found in samples with GBS will be compared to microbes that are found in samples without GBS to investigate what microbial strains or functions are protective against GBS colonization in pregnant individuals and transmission of GBS to infants during birth.
Program
CIHR Fellowship
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
473499
Name
Kennedy Katherine
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Beneficial microbes to prevent neonatal GBS disease
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Gbs; Host-Microbe Interaction; Metagenomics; Microbiome
Abstract
Streptococcus agalactiae (Group B Streptococcus; GBS), is the leading cause of invasive neonatal infections, including sepsis and meningitis. Colonized women transmit GBS to their infant during delivery in approximately 45% of births and 3% of GBS-positive infants develop GBS disease. As GBS screening during pregnancy only predicts disease in 2 of every 1000 infants, current clinical guidelines result in high rates of unnecessary antibiotic exposure, which can contribute to changes in the microbes colonizing the infant as well as increased rates of antibiotic resistance. Additionally, preventative antibiotics during delivery do not prevent late-onset (>7days after birth) GBS disease. Thus, new treatment methods are critically needed. We do not know why some GBS colonized mothers have infants with GBS disease while others do not. It is possible that beneficial vaginal microbes can protect against GBS disease. Studying the genomes of maternal vaginal microbes will allow us to discover which genes are present and what functions they have. This research will advance our understanding of the factors that influence GBS colonization and infection and ultimately inform the development of novel microbe-based treatments to prevent GBS disease. To understand the factors that influence GBS disease, healthy women undergoing vaginal, elective C-section (CS), or laboured CS will be recruited (n=50 per group) and vaginal swabs and cervical-vaginal fluid will be collected prior to delivery. Infant oral swabs, skin swabs, and stool will be collected immediately after delivery and at 1 week postpartum. Microbial DNA in these samples will be sequenced and the microbes that are found in samples with GBS will be compared to microbes that are found in samples without GBS to investigate what microbial strains or functions are protective against GBS colonization in pregnant individuals and transmission of GBS to infants during birth.
Competitiondate
202210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kennedy, Katherine
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~